Atria Investments Inc Cuts Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Atria Investments Inc cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 11.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,623 shares of the biopharmaceutical company’s stock after selling 1,405 shares during the period. Atria Investments Inc’s holdings in Amicus Therapeutics were worth $113,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Xponance Inc. grew its position in shares of Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its position in Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares during the last quarter. Arizona State Retirement System boosted its position in Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after acquiring an additional 1,577 shares during the last quarter. American International Group Inc. boosted its position in Amicus Therapeutics by 1.3% during the first quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after acquiring an additional 1,785 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Amicus Therapeutics by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 1,884 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FOLD. Morgan Stanley decreased their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 16th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald lifted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Guggenheim lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.63.

Insider Buying and Selling

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 30,401 shares of company stock valued at $352,038 in the last quarter. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $9.66 on Monday. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a market cap of $2.89 billion, a PE ratio of -28.41 and a beta of 0.68. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company’s fifty day simple moving average is $10.82 and its 200-day simple moving average is $10.58.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.